# Yellowstone Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yellowstone-bioscience

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.yellowstonebio.com/
- Total disclosed funding: $21M
- Latest round: Series A (Jun 20, 2024)
- Investors on record: 1

## About

Based in Oxford, UK, Yellowstone Bioscience Limited is a biotechnology firm that focuses on acute myeloid leukaemia and other HLA-II-expressing solid tumors, leveraging proprietary biobank research. Paresh Vyas (CSO) and Julian Hirst (CFO) are the co-founders of the company. In June 2024, Yellowstone Bioscience raised GBP 16.5 million in Series A funding led by Syncona Limited.

The company is developing therapeutic T-cell-specific molecules designed to selectively kill cancer cells while sparing healthy cells. The firm’s approach also involves a proprietary biobank of over 10,000 samples from more than 3,000 AML patients. This biobank includes samples from high-risk AML patients cured by allogeneic stem cell transplantation. The company’s lead program focuses on AML, a disease that accounts for 62% of all leukaemia deaths. In addition, Yellowstone targets peptide-Class II antigens in other common solid organ cancers that exhibit HLA-II expression, including ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer, prostate cancer, breast cancer, renal cancer, and melanoma.

The organization plans to use the June 2024 funding to advance its operations, focusing on its lead program in acute myeloid leukemia (AML) and exploring further pipeline expansions.

## Funding rounds

- Series A, Jun 20, 2024, $21M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A